Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 426 participants.
Also called NCT07614958
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 426 participants
- Sponsor
- Registry
-
NCT07614958 -
2025-524265-24-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07614958. Randomized; double masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2027-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
- Acronym
- MEDICI
- Condition
- Mixed Dyslipidemia
- Condition
- Hypercholesterolaemia
- Intervention (Drug)
- Obicetrapib 10 mg/Bempedoic Acid Placebo
- Intervention (Drug)
- Bempedoic Acid 180mg/Placebo Obicetrapib
- Lead sponsor
- A. Menarini International Licensing S.A.
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct07614958- Content hash
81846704ad51776fbbe3e1a9913aa293b8a79d2121c3542838d6f9638494c8f6